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Abstract (200 words):  
Gastro-oesophageal reflux disease (GORD) is a common comorbidity in bronchiectasis, and is often 
associated with poorer outcomes. The cause and effect relationship between GORD and 
bronchiectasis has not yet been fully elucidated and a greater understanding of the pathophysiology 
of the interaction and potential therapies is required. This review explores the underlying 
pathophysiology of GORD, its clinical presentation, risk factors, commonly applied diagnostic tools, 
and a detailed synthesis of original articles evaluating the prevalence of GORD, its influence on disease 
severity and current management strategies within the context of bronchiectasis. The prevalence of 
GORD in bronchiectasis ranges from 26%-75%. Patients with co-existing bronchiectasis and GORD 
were found to have an increased mortality and increased bronchiectasis severity, manifest by 
increased symptoms, exacerbations, hospitalisations, radiological extent and chronic infection, with 
reduced pulmonary function and quality of life. The pathogenic role of Helicobacter pylori infection in 
bronchiectasis, perhaps via aspiration of gastric contents, also warrants further investigation. Our 
index of suspicion for GORD should remain high across the spectrum of disease severity in 
bronchiectasis. Identifying GORD in bronchiectasis patients may have important therapeutic and 
prognostic implications, although clinical trial evidence that treatment targeted at GORD can improve 
outcomes in bronchiectasis is currently lacking.
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Introduction: 
Bronchiectasis is an umbrella term for patients with a chronic inflammatory lung disease characterised 
radiologically, by the permanent dilation of bronchi, and clinically, by persistent cough, sputum 
production, and recurrent respiratory tract infections.(1) Data across multiple healthcare systems 
suggest that the prevalence of bronchiectasis is increasing.(2-4) The common pathophysiological 
pathway of bronchiectasis consists of Cole’s “vicious cycle” hypothesis of infection, inflammation and 
airway structural changes.(5) The interesting feature is that the initial herald event may be a once-off 
phenomenon such as aspiration, an inhaled foreign body or pneumonia, but once initiated, the vicious 
cycle is often self-perpetuating. The clinical profile of bronchiectasis is frequently punctuated by acute 
exacerbations, which are associated with accelerated lung function decline and deterioration in 
quality of life (QoL).(6) Bronchiectasis patients are also frequently afflicted by comorbidities, often 
associated with severe disease and poor clinical outcomes, many of which confer an independent risk 
of death and might be missed unless specifically searched for.(7) 
 
Gastro-oesophageal reflux disease (GORD) comprises symptoms or end-organ complications resulting 
from the reflux of gastric contents into the oesophagus, or beyond, into the oral cavity, larynx or 
lung.(8) It is a common upper gastrointestinal condition, affecting 9-27% of Europeans, and may be 
associated with either oesophageal or extra-oesophageal syndromes.(8, 9)  Reflux may be acidic, 
weakly acidic or non-acidic (alkaline), and may be liquid, gaseous or mixed.(10) The main factors that 
determine the significance of GORD include the frequency, duration and extent of episodes as well as 
the volume, composition and destination of the refluxed contents. 
 
As both bronchiectasis and GORD are highly prevalent conditions, the possibility of an interaction has 
long been recognised. GORD has been attributed as an aetiological factor in several aetiological 
studies of bronchiectasis but is more commonly perceived as a comorbidity that may exacerbate the 
underlying lung disease. Given the potential for bronchiectasis and GORD to aggravate each other in 
a bi-directional manner, it is important to better understand the relationship and possible 
consequences of the two conditions co-existing. This area has generated significant interest despite 
the relative paucity of good-outcome data because the potential landscape for the treatment of 
GORD, both medically and surgically, is significant. This review explores the underlying 
pathophysiology of GORD, its clinical presentation, risk factors, commonly applied diagnostic tools, 
and a detailed synthesis of original articles evaluating the prevalence of GORD, its influence on disease 
severity and current management strategies within the context of bronchiectasis. 
 
Pathophysiology of GORD 
Gastro-oesophageal reflux (GOR) is a normal physiological occurrence. In health, reflux is prevented 
through the combined action of the components of the anti-reflux barrier: the lower oesophageal 
sphincter (LOS), the crural diaphragm and the anatomical flap valve.(11) GORD usually occurs in the 
event of failure of one or more of the anatomical or physiological protective mechanisms of the anti-
reflux barrier, such that the aggressive forces (injurious properties of gastric acid, bile, pepsin and 
duodenal contents) outweigh the defensive forces (anti-reflux barrier and oesophageal clearance), 
leading to histological damage in the oesophagus and extra-oesophageal organs, including the 
exposed respiratory epithelium.(12, 13) GORD typically occurs during periods of gastro-oesophageal 
junction incompetence that may be functional (due to an increased number of transient LOS 
relaxations or the presence of a hiatal hernia) or mechanical (due to reduced LOS tone, oesophageal 
body dysfunction, delayed proximal gastric emptying, or increased intragastric pressure); with age, 
gender, smoking, obesity, spicy foods, alcohol consumption, positional and physiological changes in 
respiratory mechanics and medications all potential contributing factors.(11, 12, 14) It is also 
important to consider that GORD may result from progressive incompetence of the anti-reflux barrier 
due to the failure of multiple anti-reflux mechanisms rather than one single process, with the 




GORD may manifest as typical reflux symptoms such as heartburn, acid regurgitation, chest pain, 
epigastric pain or sleep disturbances.(8, 11, 15) These clinical features together with oesophageal 
complications, including reflux oesophagitis, Barrett’s oesophagus, and adenocarcinoma, are 
collectively referred to as oesophageal syndromes.(8) Symptoms such as a hoarse voice, chronic cough 
or wheeze that may lead to laryngitis or respiratory complications are classed as extra-oesophageal 
syndromes. The prevalence of extra-oesophageal reflux is difficult to determine; extra-oesophageal 
symptoms can occur concurrently with typical GORD symptoms or in isolation.(15) It is estimated that 
approximately one third of patients with GORD have concurrent extra-oesophageal symptoms; 
however, establishing that an individual patient’s extra-oesophageal symptoms are caused by reflux 
is extremely difficult.(9) An outline of oesophageal and extra-oesophageal clinical presentations of 
GORD is presented in Figure 1. Either may be present in patients with bronchiectasis. 
 
Diagnostic assessment of GORD 
The most common approach to the diagnosis of GORD is through an accurate medical history, 
enquiring about typical symptoms and their relationship to food, posture, and stress.(15) However, 
some of the extra-oesophageal symptoms of GORD may be similar to those of bronchiectasis. 
Therefore, it is necessary to enquire as to the timing of GORD symptoms and their association with 
awakening from sleep, or the presence of respiratory symptoms or coughing after meals.(16) 
Symptom evaluation alone may be insufficient for a diagnosis of GORD due to limited sensitivity and 
speciﬁcity.(17) Symptom assessment through validated questionnaires, which ideally incorporate 
both oesophageal and extra-oesophageal symptoms so as not to limit their applicability in the setting 
of silent reflux, may be needed.(18) In the presence of typical reflux symptoms, an empirical trial of 
acid suppression therapy is often undertaken, with resolution of symptoms considered clinically 
indicative of GORD.(15) In those with persisting symptoms despite therapy, objective tools such as an 
oesophago-gastro-duodenoscopy may be used to identify secondary complications of mucosal injury 
and oesophagitis.(19) 
 
In patients without typical symptoms or where asymptomatic reflux is suspected, alternative options 
for diagnosing GORD include ambulatory 24-hour oesophageal pH monitoring, with or without 
multichannel intraluminal impedance testing – the current “gold standard” for diagnosing GORD.(10, 
15, 20-23) pH-monitoring is generally performed after cessation of acid suppression drugs for a 
minimum period of five days to allow tracking of overall oesophageal acid exposure and investigate 
whether or not a temporal relationship is present between symptoms and reflux events.(11) 
Oesophageal manometry testing is generally performed prior to insertion of the pH-impedance probe 
to ensure correct positioning for electrode placement and to rule out severe oesophageal motility 
disorders.(24) Dual-channel pH monitoring measures proximal and distal oesophageal pH, providing 
data on the frequency and duration of reflux episodes and the proximal spread of the refluxed material 
over a complete circadian cycle.(21, 22). A variation on this is telemetry capsule pH monitoring, which 
offers increased patient tolerability and the option to extend the monitoring period to 48 or 96 hours, 
but which does not allow for a combined impedance assessment.(25) Combining pH monitoring with 
multichannel intraluminal impedance allows the additional identification of acid versus weakly acid or 
non-acid reflux, and measurement of gaseous versus liquid or mixed reflux, recording GORD at all pH 
levels and enabling confirmation in patients whose diagnoses may have been missed using pH-testing 
alone.(10) This technique quantifies the type, number, composition, duration and extent of each reflux 
episode, giving an exact assessment of the proximal extent of refluxed material and a detailed 
characterisation of each reflux episode.(10, 26, 27) 
 
Diagnosis of pulmonary microaspiration 
Pulmonary micro-aspiration of duodeno-gastric contents into the lungs, hypothesised to drive the 
progression of an exaggerated bronchial inflammatory response, can be detected through various 
methods.(28, 29) This hypothesis is very difficult to test, due to both the difficulties in assessing the 
presence of reflux clinically and diagnostically, and the potential confounding effects of anti-
inflammatory and prokinetic therapies used in the treatment of bronchiectasis.(29) Although dual 
chamber pH and impedance monitoring both detect proximal reflux, the extent of reflux within the 
hypopharynx and airway is not measured. The detection of pepsin and bile salts, as markers of gastric 
and duodenal reflux, respectively, in saliva, sputum, tracheal aspirates or bronchoalveolar lavage (BAL) 
fluid have been proposed as surrogate markers of reflux aspiration.(17, 18) Pepsin has been detected 
in lung transplant recipients with GORD confirmed on oesophageal pH monitoring or impedance 
monitoring, and more recently in sputum and exhaled breath condensate (EBC) in individuals with 
bronchiectasis, suggesting that these biological markers are reliable in assessing the effect of 
pulmonary micro-aspiration in lung disease severity.(30, 31) 
 
Treatment of GORD 
Current therapy for GORD focuses on modifying risk factors, inhibiting the production of gastric acid 
and enhancing oesophageal and gastric motility.(15) Lifestyle modifications to minimise GORD include 
weight loss, avoidance of late-night meals, avoidance of food and drink that might relax the LOS, stress 
reduction and altered posture, including adapting a semi-recumbent posture when sleeping.(15, 32) 
Medical approaches include the use of antacids, histamine antagonists and proton pump inhibitor 
(PPI) therapy, as determined by the severity of GORD.(11, 15, 33, 34) The beneﬁcial eﬀect of antacids, 
with or without alginic acid, is related to the neutralisation of acid, which provides temporary 
symptomatic relief. PPIs and histamine antagonists inhibit gastric acid secretion. PPIs are thought to 
be more effective and promote faster healing than histamine antagonists. However, recent 
population-based studies have suggested that long-term PPI use may be associated with a variety of 
adverse events including osteoporosis-related hip and spine fractures, community-acquired and 
nosocomial pneumonia, vitamin B12 deficiency, various enteric and non-enteric infections, and many 
others.(35) Studies involving oesophageal multichannel intraluminal impedance have revealed a 
potential role of weakly acidic or non-acid reflux in patients with persistent symptoms despite 
treatment with a PPI.(36) PPI therapy may result in a paradoxical increase in the number and 
frequency of weakly acid and non-acid reflux events rather than eradicating the problem, and 
therefore do not provide a long-term solution for GORD.(36) The mechanism by which weakly acidic 
reflux causes GORD-related symptoms remains poorly understood but could be related to one or both 
of oesophageal distension by increased reflux volume or oesophageal hypersensitivity to weakly acidic 
reflux.(36) 
 
In cases of oesophageal dysmotility, prokinetic therapy can be trialled to speed up gastric emptying 
by increasing peristaltic muscle contractions of the lower oesophagus and strengthening the LOS, 
limiting exposure of acid to the oesophagus. More commonly used drugs are domperidone and 
metoclopramide, but the prokinetic effects of erythromycin and azithromycin should not be ignored. 
Macrolides work by increasing gastric emptying, increasing proximal stomach tone and lowering LOS 
pressure via a cholinergic pathway mediated by motilin receptors.(37) Given their success in the 
treatment of bronchiectasis exacerbations, further work into the effect of GORD and bronchiectasis 
exacerbations is needed. 
 
There is currently a growing interest in non-PPI-related therapeutic strategies for GORD with a 
resurgence in endoscopic treatment and anti-reflux surgeries, which at present are reserved for 
patients with persistence of the underlying mechanism causing GORD.(38) A Nissen’s fundoplication 
is the most commonly performed surgical procedure for GORD, consisting of a complete 360° wrap 
to create an antireflux valve at the fundus of the stomach that inhibits the regurgitation of gastric 
contents into the oesophagus. Endoscopic treatments, such as the LINX or Stretta therapy, may not 
offer the same degree of relief provided by surgery, but might represent viable alternatives for 
patients seeking relief from lifelong dependence on pharmacological therapy, its cost, associated 




Literature search: We searched electronic databases including Pubmed, Medline (Ovid), EMBASE, 
Scopus and the Cochrane Central Register of Controlled Trials (CENTRAL) for all reports published from 
inception until May 2017 using the following search string: reflux[majr] OR gastro-oesophageal 
reflux[Majr] OR GORD[tiab] OR gastroesophageal reflux[majr] OR GERD[tiab] OR duodenogastric 
reflux[Majr] OR laryngopharyngeal reflux[Majr] AND bronchiectasis[majr] OR NCFB[tiab] OR 
NCFBr[tiab]. To ensure a complete review of available studies, manual review of conference 
proceedings and review of references from selected papers was also performed. 
 
Study selection: Limits were not applied to the search strategy to enable a comprehensive search to 
be performed. However, the following article types were excluded from our qualitative synthesis: 
reviews, editorials, case reports, case series and non-English publications. Full-text articles were 
independently reviewed by two investigators with disagreements regarding eligibility resolved by 
consensus. Data on study type and design, population characteristics, diagnosis of GORD (method of 
assessment and result) and outcome variables were extracted. A positive association was defined as 
worsening of any bronchiectasis outcome associated with the presence of GORD. As bronchiectasis 
outcomes differed between studies (e.g. reduced pulmonary function, increased radiological severity, 
etc), we report bronchiectasis outcomes as defined in the study manuscripts. Due to known 
heterogeneity in the methods of GORD detection and the number of different bronchiectasis 
outcomes, a decision was made a priori not to perform a meta-analysis or generate quantitative 
summary estimates. Instead a qualitative summary in tabular format was planned, with studies 
divided into those assessing the prevalence of GORD in bronchiectasis, the role of Helicobacter pylori 





Study selection: Of 961 citations, 24 studies (n=4,605) fulfilled the eligibility criteria (Figure 1), 
including 7 prospective case control studies (n=662), 13 prospective cohort studies (n=3,375) and 4 
retrospective cohort studies (n=568). No randomised controlled trials have been performed to date. 
15 studies assessed the prevalence of GORD in bronchiectasis (n=3,679) with 2 of these incorporating 
the prevalence of pulmonary micro-aspiration in bronchiectasis (n=57); 7 assessed the role of H. pylori 
(n=662), and 2 assessed treatment options for GORD in bronchiectasis (n=264). Effects of GORD on 
markers of bronchiectasis disease severity were noted in 12 studies (n=3,876).  2 studies focussed on 
the effects of chest physiotherapy on GORD in bronchiectasis (n=62). 4 studies were paediatric-based 
(n=330); the remaining 20 (n=4, 275) were adult-based. 
 
Studies on the prevalence of GORD in bronchiectasis 
The prevalence of GORD in individuals with bronchiectasis has been explored in a number of studies 
to date.(7, 30, 31, 39-50) A range of diagnostic tools have been used, including symptom assessment, 
questionnaires and objective measurements, outlined in Table 1. Based on self-reported symptoms 
and questionnaires, the prevalence of GORD ranges from 34% to 74%.(7, 30, 47-50) Although a 
detailed clinical history of symptom presentation is recommended, this method of diagnosis is reliant 
upon the provocation of symptoms by reflux events, which in the event of asymptomatic or clinically 
silent reflux is not a reliable indicator. By comparison, according to oesophageal pH monitoring, 
prevalence ranges from 11% to 75% were noted.(30, 31, 39-42, 44-46) Such a wide spread may be 
related to several factors, such as selective investigation which may miss patients with silent reflux, 
the application of different GORD criteria, and whether tests were undertaken on or off anti-reflux 
medication. Mixed patterns of reflux are evident, with distal reflux only, proximal reflux only, and a 
mix of both demonstrated. In those with bronchiectasis, a prevalence greater than that seen in COPD 
and more than twice that of healthy controls has been reported for proximal and distal reflux.(30) 
GORD can affect patients with mild, moderate and severe bronchiectasis and appears to be 
particularly prevalent among bronchiectasis patients with co-existing NTM disease.(42, 50) The 
confirmed presence of asymptomatic reflux in 42% to 73% of bronchiectasis patients emphasises the 
importance of objective confirmation of GORD in certain individuals.(30, 42) 
 
Studies on the presence of pulmonary micro-aspiration in GORD 
Surrogate indicators of pulmonary micro-aspiration of gastric contents have also been examined n 
bronchiectasis. Pepsin in sputum samples has been detected in 26% to 70% of individuals with mild to 
moderate bronchiectasis.(30, 31) Although no significant association between oesophageal pH 
monitoring indices or lung disease severity and pepsin concentrations in sputum has been 
demonstrated to date, this has been previously observed in individuals with other types of lung 
disease.(51-53) This may be explained by isolated reflux events that could be aspirated being 
insufficiently frequent to contribute to the criteria defining GORD. A pilot study of exhaled breath 
condensate (EBC) in ten individuals with bronchiectasis found pepsin in 60%, irrespective of a 
diagnosis of GORD on oesophageal pH monitoring.(31) The EBC pH was significantly lower in 
bronchiectasis patients compared to controls and was strongly correlated with higher concentrations 
of EBC pepsin.(31) Low EBC pH may be related to several factors including airway inflammation, 
oxidative stress, bacterial colonisation or severe GORD in bronchiectasis. Low EBC pH has been related 
to severe GORD symptoms in COPD, suggesting that EBC pH may reflect acid reflux rather than 
tracheobronchial inflammation.(16) 
 
Studies on the influence of GORD on bronchiectasis severity 
The relationship between the severity of bronchiectasis and GORD remains somewhat controversial. 
Although some studies performed to date have observed significant relationships between GORD and 
markers of bronchiectasis disease severity, the majority of these have been based on a subjective 
evaluation of GORD determined by symptom evaluation, questionnaires and medication review. Three 
large prospective observational cohort studies suggest that GORD (particularly in the presence of a 
hiatal hernia) is associated with increased symptoms, increased exacerbations and hospitalisations, 
increased radiological severity, increased colonisation rates, reduced lung function and reduced 
HrQoL in bronchiectasis patients.(47-49) An increase in mortality has been described in two studies, a 
single centre study of 212 patients and a multicentre study of 986 patients.(7, 48) Koh et al were the 
first and only group using 24h oesophageal pH monitoring to report an association with increased 
radiological disease extent in their cohort of bronchiectasis patients with co-existing NTM.(42) The 
increased prevalence of GORD in bronchiectasis and NTM has also been observed among patients in 
the US bronchiectasis registry.(50) Ahmed et al described a correlation between symptoms of 
nocturnal reflux and distal reflux on pH-monitoring, which suggests that GORD may influence 
nocturnal respiratory status in some patients. Two case-control studies of GORD in bronchiectasis 
failed to observe any association with reduced lung function or other markers of disease severity. 
However, due to the difficulties in recruiting, these studies were significantly underpowered to detect 
such effects, and a single dimension of time may be insufficient to accurately reflect the relationship 
between GORD and bronchiectasis.(30, 31) 
 
Studies on the role of Helicobacter pylori in bronchiectasis 
H. pylori is a pathogenic organism linked with a number of gastric (gastritis, peptic ulcer, gastric, 
colorectal and pancreatic malignancy) and non-gastric (ischaemic heart disease, cerebrovascular 
disease, diabetes mellitus, vitamin B12 deficiency, and idiopathic thrombocytopoenic purpura) 
disorders.(54) Interestingly, a potential role has also been described for lung diseases including 
bronchiectasis (table 2), COPD and lung cancer.(55-63) Different mechanisms of action have been 
proposed, ranging from the induction of a low grade inflammatory state to the occurrence of 
molecular mimicry mechanisms.(54, 64) There are no known common factors implicated in the 
susceptibility to both bronchiectasis and H. pylori infection, but it has been hypothesised that 
aspiration or inhalation of H. pylori or its endotoxins into the respiratory tract from upper respiratory 
territories or the gastric reservoir, particularly in bronchiectasis patients with symptomatic GORD, 
could be an underlying mechanism of the pathogenic role of H. pylori in bronchiectasis.(56) Given the 
lack of bronchial findings in the majority of studies, it is unlikely that H. pylori plays a direct role in the 
pathogenesis of bronchiectasis; however, we cannot exclude an indirect role of the products of H. 
pylori in the pathogenesis of bronchiectasis. Further work is also needed to corroborate previous 
findings that suggest H. pylori may be responsible for increased disease severity, manifest by reduced 
lung function and increased radiological severity.(56, 61) 
 
Studies on the treatment of GORD in bronchiectasis 
Two retrospective studies assessing potential treatment strategies for GORD have been performed in 
the bronchiectasis population (table 3). In a recent study of 257 bronchiectasis patients with GORD, a 
comparison of 27 patients treated with long-term PPIs compared to 230 without PPI treatment, was 
performed. No significant differences were observed between groups in terms of lung function 6 
months after PPI therapy. However, there was a significant improvement in lung function in patients 
with high BMI in the PPI treatment group, thought to result from obesity causing increased 
oesophageal acid exposure time compared to the non-obese population.(65) However, there have 
been no randomised controlled trials of anti-reflux therapy in this patient population, and the effects 
of pharmacological management on other markers of disease severity, the co-occurrence of 
respiratory and GORD symptoms, and the use of respiratory medications remain to be clarified. 
 
A retrospective review of the clinical outcomes of seven patients with GORD-related deteriorated 
bronchiectasis showed that active anti-reflux treatment with Stretta radiofrequency (SRF) and/or 
laparoscopic fundoplication was beneficial to patient symptoms and outcome.(66) Patients were 
followed up for a period of one to five years. Typical GORD symptoms, respiratory symptoms, 
medication consumption and general health status were assessed during follow-up. GORD symptoms 
disappeared in five people and were significantly improved in the remaining two.(66) Complete 
remission of both respiratory symptoms and bronchiectasis exacerbations was reported in two 
patients. Four had significantly improved respiratory symptoms to mild or moderate degrees as well 
as reduced or zero bronchiectasis exacerbations, enabling them to resume normal physical and social 
functions.(66) Surgical management, with a Nissen Fundoplication, has been successfully applied to 
bronchiectasis patients awaiting transplantation, with reductions in symptoms of GORD as well as of 
lung disease.(67, 68) Antireflux surgery is not widely used in bronchiectasis but should be considered 
when medical management fails, especially when GORD remains severe in individuals with 




GORD is a common comorbidity in bronchiectasis with a prevalence ranging from 26%-75%. 
Associations between the presence of GORD and increased bronchiectasis severity were observed in 
a number of large prospective cohort studies manifest by increased symptoms, exacerbations, 
hospitalisations, radiological extent, chronic infection, and mortality, with reduced pulmonary 
function and quality of life. However, this effect was not replicated in several case control studies, 
most likely due to the small sample sizes and reduced power to detect such effects. All the above 
clinical studies of GORD in bronchiectasis are somewhat limited in that they lack a comprehensive 
multimodal assessment of GORD that can ascertain the mechanism of disease in this patient 
population which may increase the vulnerability to GORD in patients with bronchiectasis. 
 
Two of the possible mechanisms by which GORD may impact on the severity of bronchiectasis are 
vagally mediated reflex bronchoconstriction and pulmonary microaspiration. Vagally mediated reflex 
bronchoconstriction originates from the shared autonomic innervation between the tracheobronchial 
tree and the oesophagus. The presence of oesophageal acid in the distal oesophagus activates a 
GORD-induced vagal reflex arc which stimulates airway irritation, and triggers the release of potent 
mediators associated with coughing and bronchoconstriction.(69) During microaspiration, refluxed 
gastric material extends proximally to the oesophagus and then enters the hypopharynx, directly 
triggering a laryngeal or tracheal response, which may manifest as coughing, wheezing, or a sensation 
of dyspnoea, and with the potential to enter the lungs and trigger a direct intra-pulmonary 
inflammatory response.(29) This process of inflammation involves a complex cascade of cellular, 
molecular and systemic events aimed at benefitting the clearance of noxious agents from the mucosal 
surface. In most pathophysiological cases, the inflammatory response appears to be in excess of the 
normal state, and is believed to play a role in disease progression.(29) This mechanism has been 
extensively studied in CF patients, whereby higher documented levels of BAL pepsin and bile acids 
were found compared with healthy controls, confirming active reflux and micro-aspiration, not 
suppressed by PPI therapy.(52, 70) Challenge of primary bronchial epithelial cells cultured from CF 
lungs with physiologically achievable levels of primary and secondary bile acids led to increased 
release of the key pro-neutrophilic mediators IL-8 and IL-17.(71) These findings suggest that duodeno-
gastro-oesophageal reflux and subsequent micro-aspiration may contribute to the neutrophilic 
inflammation that is a hallmark of suppurative lung diseases.(72) 
 
Other possible explanations for pulmonary aspiration secondary to GORD may be related to 
swallowing dysfunction in bronchiectasis. Precise coordination between swallowing and respiration is 
necessary, with the swallowing reflex an important defence against airway infection and 
aspiration.(16) Compared to healthy controls, the swallowing reflex may be impaired in patients with 
bronchiectasis, with a lack of coordination of the pharyngeal musculature and disruption of the 
breathing–swallowing coordination which, if altered, may increase the risk of aspiration in patients 
with bronchiectasis and contribute to exacerbations. Swallowing dysfunction may result from a range 
of pathologies, including neurological impairment, vocal cord injury, surgery, and radiation and is 
often overlooked as an aetiological cause of bronchiectasis. 
 
It has long been postulated that the development of an abdomino-thoracic pressure gradient in 
patients with chronic respiratory disease may drive reflux and gastric aspiration.(29) Pulmonary 
hyperinflation contributes to flattening of the hemi-diaphragms and diaphragmatic dysfunction, which 
not only reduces the diaphragmatic crural support augmenting lower oesophageal pressures, but also 
changes the angle of the oesophagus, making it easier for reflux to occur. In primary lung disease, the 
intra-thoracic pressure is negative in relation to the abdominal cavity and varies during the respiratory 
cycle. As such, pre-existing LOS incompetence may be worsened by factors producing an increased 
trans-diaphragmatic pressure gradient, e.g. increased negative intra-thoracic pressure during 
inspiration and bouts of coughing, or with progressive bronchoconstriction of the airways.(49) 
Heightened anxiety is also known to aggravate GORD symptoms by increasing acid production.(73) As 
increased anxiety is common in bronchiectasis, this may be an additional contributory factor to 
GORD.(7, 74) Respiratory medications, including beta agonists, anticholinergics and corticosteroids, 
may alter oesophageal function by reducing LOS pressure or oesophageal motility.(18, 75) However, 
this association could also be a reflection of the severity of lung disease rather than the specific 
physiological effects of these medications on oesophageal function, therefore further exploration of 
the cause and effect relationship between respiratory medications and GORD in bronchiectasis is 
needed. 
 
Although oesophageal motility studies have not yet been extensively applied in bronchiectasis, one 
study using conventional manometry showed abnormal results in 71% of bronchiectasis patients, 
manifest by LOS hypotonia in 57% of patients and upper oesophageal sphincter hypotonia in 14%.(44) 
This would be expected to be relatively low in a healthy patient population. An increased prevalence 
of hiatal hernias has also been reported in patients with bronchiectasis.(49) A hiatal hernia occurs 
when part of the stomach protrudes into the thoracic cavity through the oesophageal hiatus of the 
diaphragm due to disruption of the anti-reflux barrier. If the anatomical flap valve disrupts, the LOS 
moves above the crural diaphragm, causing it to lose its synergistic configuration, hence both the LOS 
and diaphragm sphincters become appreciably weaker, compromising oesophageal acid clearance 
and facilitating the development of reflux.(11, 76) Pandolﬁno et al clearly demonstrated that a hiatal 
hernia was associated with an increased distensibility of the gastro-oesophageal junction, increasing 
the risk of liquid reﬂux and contributing to the increased acid exposure observed in patients with hiatal 
hernias.(77) The presence of a post-prandial acid pocket, a layer of unbuffered acidic gastric juice that 
sits on top of a meal, may be located more proximally or above the crural diaphragm in the presence 
of a large hiatal hernia, resulting in an increased number of acid reflux episodes during transient LOS 
relaxations.(78) Treatment with alginate-antacids and azithromycin have been shown to abolish or 
reduce the pocket, reducing acid oesophageal acid exposure. Azithromycin has been shown to reduce 
exacerbations in bronchiectasis and it is therefore tempting to speculate that perhaps some of its 
therapeutic benefit may relate to its ability to treat reflux.(79, 80) 
A deficient mucus barrier function may play a role in facilitating lung injury associated with gastric 
aspiration.(29) Mucus hypersecretion is a common endpoint in many respiratory diseases, often 
arising as a result of increased release of mucin granules by epithelial goblet cells or IL-8 driven 
increased gland-based secretion.(29) In patients with impaired mucociliary clearance, the underlying 
tissues may become more susceptible to damage with an accumulation of pathogenic microbial 
organisms from elsewhere in the respiratory or gastro-intestinal tracts. Inflammatory responses may 
also be driven in part by the presence of specific receptors within the epithelium. Preliminary data 
suggests that some receptors may be triggered by the presence of gastric juice, pepsin and bile by 
receptor-mediated endocytosis.(81, 82) Uptake of pepsin in non-acid reflux was shown to cause 
mitochondrial damage by becoming reactivated inside the cell, changing the expression of several 
genes implicated in stress and toxicity. Irreversible inhibitors of peptic activity hold promise as a new 
therapy for reflux.(81) 
 
The potential for horizontal transmission of microorganisms between the gut-lung axis may indicate 
that the upper gastrointestinal tract could act as a potential reservoir of microorganisms.(83) Chronic 
colonisation with Pseudomonas aeruginosa (P. aeruginosa) has been shown in several studies to be 
an independent predictor of mortality and lung function decline in bronchiectasis.(84-86) Horizontal 
transmission may be suggested by the demonstrated association between reflux and P. aeruginosa 
positivity in CF.(87, 88) After adjusting for age and FEV1, total reflux burden was found to be 
associated with P. aeruginosa positivity, suggesting that an increased reflux burden may predispose 
patients to P. aeruginosa infection and worse lung function.(87) More recently, similar bacterial 
profiles of CF sputum and gastric juice samples were demonstrated, which were distinct from non-CF 
gastric juice, perhaps providing novel evidence of an aerodigestive microbiome in CF.(88) However, it 
is difficult to establish whether cross-infection relates to swallowing of sputum leading to seeding of 
the gastrointestinal microbiome or if reflux and aspiration into the lungs may be causative. The 
microbiome in bronchiectasis is frequently dominated by enteric Gram-negative organisms suggesting 
that the lower airway is constantly being “replenished” by the upper airway, giving plausibility to there 
being a link in health and disease between the gut, the upper airway and the lung.(89) 
Recent research investigating the impact of bile on the behaviour of P. aeruginosa and other CF-
associated respiratory pathogens showed that bile increases biofilm formation and quorum sensing in 
P. aeruginosa, driving the switch from acute to persistent infection.(90) Bile also modulates biofilm 
formation in a range of other CF-associated respiratory pathogens, including Burkholderia cepacia and 
Staphylococcus aureus, suggesting, perhaps, that GORD-derived bile could be a host determinant 
contributing to chronic respiratory infection in chronic suppurative lung diseases.(90) 
 
A mix of demographic factors may also increase the risk of GORD in bronchiectasis. Older age and 
female sex are well-described risk factors for GORD, and given the median age and female 
predominance of bronchiectasis patients, an increased co-existence of the two is perhaps not 
surprising.(7) A larger body mass index is also a risk for GORD, increasing as BMI increases.(91) A 
greater BMI has been demonstrated in bronchiectasis patients with GORD, and may impact on the 
contour of the diaphragm, increasing the elastic work of breathing.(49) When combined with 
respiratory-related risk factors, this may increase the contribution of a higher BMI to GORD in 
bronchiectasis. Comorbidities, such as ischaemic heart disease, have also been associated with a 
heightened risk of GORD and have been shown to occur frequently and contribute to mortality in 
patients with bronchiectasis.(7) Whether these are independent variables, common consequences of 





In conclusion, GORD is a common comorbidity in patients with bronchiectasis and has a variety of 
clinical presentations. The index of clinical suspicion should remain high across the spectrum of 
disease severity in bronchiectasis, and objective measures should be used for diagnostic confirmation 
where possible due to high detection rates of asymptomatic or clinically silent reflux. The presence of 
GORD is associated with increased disease severity and mortality in patients with bronchiectasis. 
Identifying GORD in bronchiectasis patients may have important therapeutic and prognostic 
implications, although clinical trial evidence that treatment targeted at GORD can improve outcomes 
in bronchiectasis is currently lacking. 
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Figure 1 legend: Representation of the working definition of gastro-oesophageal reflux disease (GORD) 
encompassing oesophageal and extra-oesophageal end-organ effects and complications. Adapted 







Figure 2 legend: Synthesis of literature search  
 
 
Table 1: Summary of clinical studies of prevalence of gastro-oesophageal reflux disease and 
associations with disease severity in bronchiectasis  
Original 
paper 

















Prevalence of reflux = 42% using DeMeester 
score on pH monitoring 
Positive  correlation with symptoms of 
nocturnal reflux and distal reflux on pH-
monitoring 
No micro-aspiration of tracheal contents 



















Prevalence of reflux = 41% using  DeMeester 
score on pH monitoring 
Chest physiotherapy including postural 
drainage, percussion and forced expiration 
techniques in different positions did not 
induce or increase the incidence of reflux 
events in bronchiectasis or chronic bronchitis 



















Prevalence of distal reflux = 75% using 
DeMeester score on pH monitoring 
Prevalence of proximal reflux = 50% on pH 
monitoring 
Poor concordance noted between symptoms 
and pH diagnosis of GORD 
Increased oesophageal length noted in 
bronchiectasis patients 















Prevalence of reflux = 26% using DeMeester 
score on pH monitoring 
Prevalence of clinically silent reflux = 73% (no 
reflux on symptom assessment in 27%) 
Presence of GORD associated with: 
• Increased positivity for AFB on 
sputum smear 
• Increased radiological lobar extent of 















Prevalence of GORD = 32% using: 
• Barium swallow alone 67% 
• Milk scan alone 21% 
• Combination of both radiological 
procedures 12% 


















Prevalence of reflux = 50%  using DeMeester 
score on pH monitoring 
Bronchiectasis patients had highest 
prevalence of GORD and highest mean 
DeMeester scores compared to all other lung 
diseases 
Abnormal manometry noted in 71% with LOS 
hypotonia in 57% and UOS hypotonia in 14% 











Prevalence of GORD = 11% 
where clinically 
indicated 












Prevalence of reflux = 40%  using  DeMeester 
score on pH monitoring 
57% of all bronchiectasis patients experienced 
GORD during at least one physiotherapy task 
but irrespective of GORD diagnosis, there 
were fewer distal reflux episodes compared to 
background reflux time during all 
physiotherapy interventions of PEP, 6MWT 
and upper limb movements. 
No significant difference in reflux with any 














Prevalence of reflux = 74% 
Presence of GORD associated with: 
• Increased cough severity 
contributing to reduced HrQoL  
• Increased sputum inflammatory 
markers 
• Reduced FEV1% predicted 
• Increased radiological severity 
• Increased chronic colonisation and 
polymicrobial culture growth 
• Increased exacerbations 














Prevalence of reflux = 40% using 
questionnaires 
Of those, clinically silent reflux = 42% using 
dual-probe pH monitoring 

















Prevalence of symptomatic reflux on PPI = 41% 
Prevalence of confirmed hiatal hernia = 36% 
Presence of a hiatal hernia associated with: 
• Increased prevalence of GORD 
• Increased no. of lobes affected 
• Cystic bronchiectasis 
• Decreased parenchymal attenuation 
• Reduced FEV1% 














Prevalence of reflux = 34% 
Presence of GORD associated with: 
• Increased symptoms (cough, sputum 
production and wheeze) 
• Increased exacerbations and 
hospitalisations 
• Increased lobar extent and cystic 
bronchiectasis 
• Reduced FEV1% 
• Increased P. aeruginosa colonisation 
and polymicrobial culture growth 
• Increased disease severity (BSI) OR 
2.2 (95% CI 1.1-6.7) 
• Increased mortality OR 2.5 (95% CI 
1.1-7.8) 
















Prevalence of reflux = 40% using definition of 
positive distal AND proximal reflux on 
oesophageal pH monitoring 
Prevalence of reflux = 70% using sputum 
pepsin and 60% using exhaled breath 
condensate (EBC) pepsin 
Presence of EBC pepsin associated with: 
• Moderate correlation of sputum 
pepsin and EBC pepsin 
• No correlation of EBC pepsin with 
total DeMeester score, distal reflux 
index or proximal reflux index on 
oesophageal pH monitoring 













Prevalence of reflux = 34%  
Presence of GORD associated with:  
• Increased mortality (GORD non-













Prevalence of reflux = 47% 
Presence of GORD associated with: 
• NTM disease in bronchiectasis (GORD 
NTM 51%, GORD non-NTM 40%; 
p<0.01) 

















High seroprevalence of H. pylori among 
bronchiectasis patients vs. controls = 76% vs. 
54%; p=0.001 
Positive correlation with increased sputum 
volume and age 




















Symptomatic prevalence of reflux = 32% 
Positive anti- H. Pylori Cag A serology in of 
bronchiectasis patients vs. controls = 24% vs. 
12%; p=0.03 
No association with anti- H. Pylori Cag A and 
lung function, sputum volume, respiratory 
symptoms or upper gastrointestinal symptoms 
Positive correlation of patients reporting acid 
reflux or upper abdominal distension with 












PCR for H. Pylori negative in all BAL samples 







H. pylori serology 
Bronchial brush 









Seroprevalence of H. pylori noted in 58% 
bronchiectasis patients vs. 68% healthy 
controls. 
H. pylori was not isolated from protected brush 
or mucosal biopsy samples in any patient and 
urease test was negative in all patients.  
No associations were observed between H. 
pylori seropositivity and sputum volume, lung 









search of a 
primary 
malignancy (n=8) 
H. pylori serology 
Immunostaining 
of bronchial 
biopsy for anti- H. 





Seroprevalence of  H. pylori among 
bronchiectasis patients = 46% 
No evidence of H. pylori was obtained in the 










H. pylori serology 
Bronchoalveolar 
lavage (BAL) fluid 
PCR and ELISA 
PCR in surgically 





Seroprevalence of H. pylori noted in 92% 
bronchiectasis patients vs. 80% controls. 
PCR for  H. pylori negative in all BAL samples 
from patients and controls and in surgically 








lavage (BAL) fluid 
PCR and culture 
Gastric juice PCR 
and culture 





PCR for  H. pylori in BAL  positive in 22% 
bronchiectasis patients vs. 19% controls 
(p>0.05) 
PCR for  H. pylori in gastric juice positive in 39% 
bronchiectasis patients vs. 44% controls 
(p>0.05) 
Urea breath test positive in 27% bronchiectasis 
patients vs. 19% controls (p>0.05) 
 No associations was observed between BAL H. 
pylori positivity and lung function. 
Positive association between BAL  H. pylori 
positivity and increased CT score was observed 
(p<0.05) 

























Laparoscopic fundoplication (n=2) 
Laparoscopic fundoplication with repair of 
hiatal hernia (n=2) 
Stretta radiofrequency (n=2) 
Combined laparoscopic fundoplication and  
Stretta radiofrequency (n=1) 
Significant reduction in reflux and respiratory 
symptoms and exacerbations/hospitalisations 
noted on follow-up with negation of therapy 
for GORD in n=4 patients. 
Ahn 2016(65) Bronchiectasis 
and GORD with 
(n=27) or without 
(n=250) long-
term PPI therapy 




No significant differences were observed 
between groups in terms of lung function 6 
months after PPI therapy.  
A significant improvement in lung function was 
noted in patients with high BMI in the PPI 
treatment group that was significantly related 
to the severity of obesity. 
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